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Abstract
Background: Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are common early-onset malignancies.
Their causes are largely unknown but infectious etiology has been implicated. Type 1 diabetes (T1D) is an autoimmune
disease for which infectious triggers of disease onset have been sought and increasing pointing to enteroviruses. Based on
our previous results on co-morbidity between leukemia and T1D, we updated the Swedish dataset and focused on early
onset leukemias in patients who had been hospitalized for T1D, comparing to those not hospitalized for T1D.
Methods and Findings: Standardized incidence ratios (SIRs) were calculated for leukemia in 24,052 patients hospitalized for
T1D covering years 1964 through 2008. T1D patients were included if hospitalized before age 21 years. Practically all
Swedish children and adolescents with T1D are hospitalized at the start of insulin treatment. SIR for ALL was 8.30 (N=18,
95% confidence interval 4.91–13.14) when diagnosed at age 10 to 20 years after hospitalization for T1D and it was 3.51 (13,
1.86–6.02) before hospitalization for T1D. The SIR for ALL was 19.85 (N=33, 13.74–27.76) and that for AML was 25.28 (8,
10.80–50.06) when the leukemias were diagnosed within the year of T1D hospitalization. The SIRs increased to 38.97 (26,
25.43–57.18) and 40.11 (8, 17.13–79.42) when T1D was diagnosed between ages 10 to 20 years. No consistent time-
dependent changes were found in leukemia risk.
Conclusion: A shared infectious etiology could be a plausible explanation to the observed co-morbidity. Other possible
contributing factors could be insulin therapy or T1D related metabolic disturbances.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common
childhood malignancy. The underlying causes are largely un-
known beyond ionizing radiation and the recently detected
susceptibility genes [1,2,3]. However, an infectious etiology has
been strongly implicated but the agents have evaded identification
[4,5,6,7,8]. Acute myeloid leukemia (AML) is an adult disease but
a few percent of cases occur in the childhood [9]. Viruses, solvents,
ionizing radiation and smoking have been implicated in adults but
the causes of childhood cases are unknown [9]. Type 1 diabetes
mellitus (T1D) is an early-onset autoimmune disease in which
immune response is directed against the insulin-producing beta
cells of the pancreas, resulting in insulin-dependence. The
autoimmune process is thought to be triggered in susceptible
individuals by unknown factors [10,11]. T1D is increasingly
thought to have a viral basis, probably a consequence through
genetically determined aberrant response to an enteroviral in-
fection [12,13]. Enterovirus RNA has been demonstrated in the
blood and pancreatic tissue of early onset T1D patients [12].
Family history is an important risk factor for T1D for which the
HLA region is the most important contributor [13,14,15]. The
HLA locus regulates the response to many viral infections and
even other T1D susceptibility loci are relevant to antiviral actions,
including the IFIH1 gene modulating innate immunity [12].
Recently, genetic variation around the gene encoding IKZF1,
a regulator of lymphocyte development and immune homeostasis,
has been shown to confer susceptibility to both childhood ALL
and T1D [1,16]. Previous epidemiological studies have shown
significant correlations in incidence between ALL and T1D at
both the international and regional level, with potential but
unproven links with an infectious etiology [17,18].
In a previous study of cancer risk in T1D patients, we reported
increased risk of leukemia, stomach and skin cancers [19]. In view
of the increasing data on the possible viral etiology of T1D, we
updated the Swedish dataset and investigated in detail the
associations of early-onset leukemia with T1D.
Methods
The analyses were carried out by linking T1D patients
(N=24,052) from the nation-wide Hospital Discharge Registry
(years 1964 to 2008) with cancer data from the Swedish Cancer
Registry, collected in the Family-Cancer Database (1964 to 2008)
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of T1D patients was as in the present study but cancer follow-up
was extended by 2 more years for the present study [19].
Practically all Swedish children and adolescents with T1D are
hospitalized at the start of insulin treatment [20], hence selection
bias is not a source of confounding. Also the diagnostic accuracy is
high [21]. T1D was defined to include patients whose age at first
hospitalization for diabetes was before age 21. In the previous
study we assessed how well this age limit was able to discriminate
T1D from other types of diabetes. According to International
Classification of Diseases version 10, listing T1D as an in-
dependent disease, 98% of diabetics diagnosed before age 21 years
were T1D patients [19].
Person-years were calculated from the start of follow-up at
hospitalization for T1D until diagnosis of cancer, death, emigra-
tion, or closing date on December 31, 2008. Alternative analyses
considered leukemia diagnosed before hospitalization for T1D or
that T1D and leukemia were diagnosed within one year of each
other. Standardized incidence ratios (SIRs) were calculated as the
ratio of observed (O) to expected number of cases. Expected rates
were calculated for age (10-year groups), gender, period of
diagnosis (10-year bands) and region (4 groups) and compared
with individuals without hospitalization for T1D [19]. As T1D is
a rare disease, the expected rate without hospitalization for T1D
was essentially the population rate.
The study was approved by the ethics committee at Lund
University.
Results
SIRs for ALL, AML, chronic lymphocytic leukemia (CLL) and
chronic myeloid leukemia (CML) following hospitalization for
T1D are detailed in Table 1. SIRs were significantly increased for
both ALL (5.70, 3.68–8.43) and AML (2.57, 1.02–5.32) but not for
either CLL or CML. The highest SIR for ALL of 8.30 (4.91–
13.14) was attained for a diagnosis between age 10 and 20 years
following hospitalization for T1D. When diagnosed before
hospitalization for T1D, the SIR for ALL was 3.51 (1.86–6.02)
and that for AML was 4.80 (1.52–11.30) at age 10 to 20 years.
Overall across all ages the SIRs for ALL and AML were highly
significant at age 10 to 20 years (5.37, 3.65–7.64 and 4.50, 1.92–
8.92) and at age 0 to 50 years (4.17, 3.07–5.53 and 3.77, 2.05–
6.34). While stratification by sex showed higher ALL rates for
females and higher AML rates for males, all the key findings were
significant for both males and females (data not shown).
In Table 1, the highest risks of ALL and AML were observed in
patients first hospitalized for T1D at age 10 to 20 years which age
group also showed the highest incidence for T1D hospitalization.
Considering mean ages for T1D hospitalization for ‘leukemia
diagnosis before or after hospitalization for T1D’ in Table 1, for
ALL these were 7.6 years (ALL diagnosis ,10 years), 14.3 years
(ALL diagnosis 10–20 years) and 12.8 years (ALL diagnosis 21–50
years); the corresponding median ages for T1D hospitalization
relating to AML were 11.5, 16.9 and 15.3 years.
Age-specific incidence of leukemia in T1D patients is shown in
Fig. 1 in comparison to the Swedish background rates. The
incidence in ALL among T1D patients was essentially equal in age
bands 0–9 y and 10–19 y but because the background incidence
declined with age the SIRs were higher for the latter age group as
was shown in Table 1. For AML, the highest incidence in T1D
patients was in age group 10–19 y.
The SIRs were very high if leukemia was diagnosed within one
year of hospitalization for T1D; the SIR for ALL was 28.59 (15.95–
47.27) and that for AML was 28.50 (5.37–84.36)(Table 2). They
were even higher, 72.87 (39.70–122.59) and 43.27 (8.16–128.09),
when T1D patients were hospitalized at age 10 to 20 years. In
contrast, if events were separated by more than one year, the
respective SIRs were 2.59 (1.23–4.77) and 1.55 (0.40–4.02). When
Table 1. SIRs for leukemia in T1DM patients according to age at leukemia diagnosis.
Leukemia Age at diagnostic for leukemia (years)
,10 10 – 20 21 – 50 All
O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Leukemia diagnosed after hospitalization for T1D
ALL 3 2.31 0.43 6.83 18 8.30** 4.91 13.14 4 3.63 0.95 9.40 25 5.70** 3.68 8.43
CLL 0 0 3 9.48* 1.79 28.05 3 4.09 0.77 12.11
AML 0 3 3.97 0.76 11.75 4 2.31 0.60 5.97 7 2.57* 1.02 5.32
CML 0 0 3 2.33 0.44 6.89 3 1.70 0.32 5.03
Leukemia diagnosed before hospitalization for T1D
ALL 10 1.60 0.76 2.94 13 3.51** 1.86 6.02 0 23 3.22** 2.04 4.84
CLL 0 0 0 0
AML 2 2.33 0.22 8.58 5 4.80* 1.52 11.30 0 7 6.91** 2.74 14.31
CML 0 0 0 0
Leukemia diagnosed before or after hospitalization for T1D
ALL 13 1.72 0.91 2.95 31 5.37** 3.65 7.64 4 3.63 0.95 9.40 48 4.17** 3.07 5.53
CLL 0 0 3 9.48* 1.79 28.05 3 4.09 0.77 12.11
AML 2 2.33 0.22 8.58 8 4.50* 1.92 8.92 4 2.31 0.60 5.97 14 3.77* 2.05 6.34
CML 0 0 3 2.33 0.44 6.89 3 1.70 0.32 5.03
O, observed; SIR, standardized incidence ratio; CI, confidence interval; *P,0.05, **P,0.01.
Case numbers in the reference population ALL: 1733 (,10 y), 701 (10–20 y), 562 (21–50 y), 2996 (total); CLL: 55 (,10 y), 15 (10–20 y), 728 (21–50 y), 798 (total); AML:
301 (,10 y), 296 (10–20 y), 1506 (21–50 y), 2103 (total); CML: 88 (,10 y), 93 (10–20 y), 1201 (21–50 y), 1382 (total).
doi:10.1371/journal.pone.0039523.t001
Viral Etiology?
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39523hospitalized for T1D before age 10, the only significant increase of
5.85 was for ALL diagnosed within one year (N=7, 95%CI 2.49–
11.27, before or after T1D hospitalization) (data not shown).
According to Table 2, the majority of T1D hospitalizations and
leukemia diagnoses coincided with the same year. The mean
calendar time difference between the two events depended
however on the age at T1D hospitalization. For ‘leukemia
diagnosed before or after hospitalization for T1D’ the median
time difference was only 0.8 years for ALL and 0.7 year for AML
in the most common leukemia diagnostic group of 10 to 20 years.
For leukemias diagnosed ,10 year the mean difference was 3.5
years for ALL and 9.0 years for AML; for leukemias diagnosed
between 21 and 50 years the mean difference was 13.8 years for
ALL and 18.5 years for AML.
Figure 1. Age-specific incidence of leukemia in T1D patients (symbols in three age bands, 0–9 y, 10–19 y and 20–49 y) compared to
the Swedish background rate (solid lines in 10–year age bands). The case numbers for T1D patients are shown in Table 1 and those for the
background rates in footnote to Table 1.
doi:10.1371/journal.pone.0039523.g001
Table 2. SIRs for leukemia in T1D patients according to time at hospitalization for T1D and age at T1D diagnosis.
Leukemia
(T1D diagnosis at age
10–20 years) Time at hospitalization for T1D (years)
Within 1 year More than 1 year
O SIR 95% CI O SIR 95% CI
Leukemia diagnosed after hospitalization for T1D
ALL 15 28.59** 15.95 47.27 10 2.59* 1.23 4.77
ALL (T1D 10-20 y) 14 72.87** 39.70 122.59 6 3.58* 1.29 7.85
AML 3 28.50** 5.37 84.36 4 1.55 0.40 4.02
AML (T1D 10-20 y) 3 43.27** 8.16 128.09 4 2.11 0.55 5.45
Leukemia diagnosed before hospitalization for T1D
ALL 18 15.99** 9.61 25.02 5 0.76 0.24 1.79
ALL (T1D 10-20 y) 12 25.26** 12.99 44.27 3 0.62 0.12 1.84
AML 5 23.68 7.47 55.69 2 2.20 0.21 8.07
AML (T1D 10-20 y) 5 38.42 12.12 90.38 1 1.43 0.00 8.21
Leukemia diagnosed before OR after hospitalization for T1D
ALL 33 19.85** 13.74 27.76 15 1.38 0.95 2.97
ALL (T1D 10-20 y) 26 38.97** 25.43 57.18 9 1.58 0.89 4.77
AML 8 25.28** 10.80 50.06 6 1.77 0.56 3.41
AML (T1D 10-20 y) 8 40.11** 17.13 79.42 5 1.87 0.49 5.89
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Analyses by calendar period showed that there was no significant
time trend for ALL or AML. The number of hospitalizations for
T1D (1 to 3 compared to 3+) did not influence the risk for ALL
(4.10, 2.72–5.93 vs 4.29, 2.62–6.64) and for AML the only
significant SIR was for those hospitalized 1 to 3 times.
Discussion
Outside therapeutic settings and exclusive of Down syndrome
and co-twin affected with ALL, the present risks for ALL and
AML are remarkably high [22,23]. For example, the analysis of
sibship size as a proxy of infectious etiology showed an effect for
ALL but not for AML, yet the overall risk was only 1.3 (4 or more
siblings vs. 1) but it increased 2.1-fold in those diagnosed below age
6 years [6]. Clearly, the present high risks require explanation,
particularly as the hospitalized T1D population is not a small
subgroup of all patients but practically all Swedish children and
adolescents diagnosed with T1D, hospitalized at the start of insulin
treatment [20]. There was also an indication that CLL, with a very
different age distribution compared to T1D, might be related to
T1D but with 3 cases the evidence awaits further confirmation.
The main limitation of the present study is that it is purely
epidemiological, lacking any data on serological analysis, but, at
the same token, the diagnostic data on leukemia and T1D should
be highly reliable [21,24]. Demanding virological proof for the
present study appears overwhelming because conclusive proof has
yet been obtained neither for ALL nor T1D, in spite of numerous
attempts [4,7,11].
Our findings provide strong evidence for a relationship between
early-onset leukemia risk and T1D. While it is possible that insulin
therapy causes leukaemigenesis directly through its growth-pro-
motion effects, risks were also increased prior to first hospitalization
forT1D.Itispossible,althoughunlikely,thatthehighglucoselevels
and metabolic disturbance before the start of insulin therapy might
trigger leukemia, in an analogous fashion to the increased risk of
cancer associated with type 2 diabetes [25]. As the length of time to
achieve stable glucose control (number of hospitalizations is a proxy
for labile glucose levels) was not correlated with risk, this strongly
argues against such an explanation. Furthermore, there was no
evidence of a time trends, which should exclude strong environ-
mental or treatment-related changes, assuming that the control of
glucose levels has improved with time. Shared symptoms of
generalized weakness and fatigue for childhood leukemia and
T1D may contribute to the coincident detection, but there is no
reason to doubt diagnostic accuracy. Whether autoimmunity itself
would trigger leukemia is also a theoretical but not a likely option
because it would not explain the coincident diagnosis of the two
diseases and the decreasing leukemia risk past age 20 years. Finally
by exclusion, our findings coupled with epidemiological and other
data provide support for a common infective basis for the observed
co-morbidity, which most probably could be viral in origin. It is not
clearatwhatagespancreatictissuewouldbemostvulnerabletoviral
damagebuthighpositivityforenteroviral capsidproteinshavebeen
found in pancreatic islets in72 patients with a mean age of 13 years,
well within the present age range [26]. As genetic susceptibility to
T1D and ALL is now well established an aberrant response to viral
challenge leading to both diseases would provide an attractive basis
for the observed co-morbidity.
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